AstraZeneca (LON:AZN) Stock Rating Reaffirmed as “Buy” by Jefferies Financial Group

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reaffirmed by research analysts at Jefferies Financial Group in a research note issued on Tuesday, Digital Look reports. They presently have a £175 price objective on the biopharmaceutical company’s stock. Jefferies Financial Group’s price target suggests a potential upside of 40.09% from the company’s current price.

AZN has been the topic of a number of other research reports. Berenberg Bank reiterated a “buy” rating and set a £175 target price on shares of AstraZeneca in a research note on Wednesday, October 7th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a £117 price target on shares of AstraZeneca in a report on Tuesday, September 29th. Royal Bank Of Canada restated an “outperform” rating and issued a £145 price target on shares of AstraZeneca in a research note on Tuesday, September 8th. Finally, Citigroup boosted their price target on AstraZeneca from £175 to £178 and gave the company a “buy” rating in a research note on Tuesday, July 28th. Six analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, AstraZeneca has a consensus rating of “Moderate Buy” and an average target price of £153.57.

AstraZeneca Trading Up 0.7%

Shares of LON:AZN opened at £124.92 on Tuesday. AstraZeneca has a 12-month low of £114.04 and a 12-month high of £157.32. The stock has a market cap of £193.74 billion, a PE ratio of 18.70, a P/E/G ratio of 0.86 and a beta of 0.20. The business has a 50 day moving average of £121.01 and a 200-day moving average of £131.12. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 64.10.

Insider Buying and Selling

In other AstraZeneca news, insider Michel Demare acquired 2,500 shares of the company’s stock in a transaction on Monday, September 14th. The stock was acquired at an average price of £121.21 per share, for a total transaction of £303,025. Corporate insiders own 0.15% of the company’s stock.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.